EU's IMI funds eight more projects to develop new drugs; Patent Court
The European Union’s Innovative Medicines Initiative (IMI), Europe's largest public-private partnership in the biopharmaceutical sector, yesterday launched its second wave of research projects. With a total budget of 172 million euros ($240.8 million), the eight new projects will aim to develop new treatments for cancer, rheumatoid arthritis and infectious diseases.
The project consortia include 65 teams from 21 members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) who will work together with partners from 103 academic teams, 23 small and medium-sized enterprises, and two patient organizations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze